Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
NCT00815633 · Joshua Zeichner · PHASE4 · terminated · last registry update 2018-05-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Failed to enroll patients. There is no data or results for this study.” | – | Registry record, Joshua Zeichner |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-03-16Also stopped (terminated): Massachusetts General Hospital, MEDI-507 (NCT00113646)
- 2018-01-26Also stopped (terminated): The Cleveland Clinic, Alefacept (NCT01267643)
- 2017-10-02Results posted on the registry: Mayo Clinic, Alefacept (NCT00438802)
- 2017-07-27Also stopped (terminated): Emory University, Alefacept (NCT01319851)
- 2017-07-06Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Alefacept + Placebo (NCT00965458)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision